Quantcast
Home » News
Home » News

FDA approves Biogen's MS drug Plegridy

Published August 15, 2014 7:09 pm
This is an archived article that was published on sltrib.com in 2014, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

Cambridge, Mass. • Biogen Idec said Friday that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.

The company said the Food and Drug Administration cleared the injectable drug, dubbed Plegridy, after reviewing results from a study that involved more than 1,500 people with the disease.

Multiple sclerosis is a disease of the immune system in which the body attacks the brain and spinal cord.



Its symptoms can come and go, often reappearing months later.

The European Commission recently approved Plegridy.

Biogen also markets the multiple sclerosis drugs Avonex and Tysabri.

Shares of Biogen Idec Inc. ended regular trading up $5.46, or 1.6 percent, to $342.47 on Friday.

The stock is up 22 percent this year.

 

 

 

USER COMMENTS
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
comments powered by Disqus